High enantiomeric purity dexanabinol for pharmaceutical compositions
OwnerHaim Aviv, Raphael Bar +2inventors
InventorsHaim Aviv, Raphael Bar, Michael Schickler, Shimon Amselem
Life of this patent
Estimating the term…
Abstract
The present invention relates to a synthetic cannabinoid, dexanabinol, of enantiomeric purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound. The present invention also relates to pharmaceutical grade compositions comprising said compound of high enantiomeric purity, and uses thereof for prevention and treatment of neurological disorders, chronic degenerative diseases, CNS poisoning, cognitive impairment, inflammatory diseases or disorders, autoimmune diseases or disorders, pain, emesis, glaucoma and wasting syndromes.
Claims24
A compound of formula (I):
- Formula I
- 9
- having the (3S,4S) configuration and being in enantiomeric excess of at least 99.90% over the (3R,4R) enantiomer, or a pharmaceutically acceptable salt, ester or solvate of said compound.
A pharmaceutical composition comprising as an active ingredient dexanabinol, a compound of formula (I):
- Formula I
- 10
- having the (3S,4S) configuration and being in enantiomeric excess of at least 99.90% over the (3R,4R) enantiomer, or a pharmaceutically acceptable salt, ester or solvate of said compound.
Dependencies are inferred from the claim text.